Study summary

Two more IgA nephropathy drugs await FDA decisions by December 2026

FDA decisions due in late 2026 · Phase 3 programs · FDA decisions expected November-December 2026

What was tested

Povetacicept (Vertex), a dual BAFF/APRIL blocker, and ravulizumab (Alexion), a complement C5 blocker, under FDA review for IgA nephropathy.

What they found

• Povetacicept has an FDA target date of November 30, 2026.
• A ravulizumab decision is expected in the fourth quarter of 2026.

What it means

If approved, people would have at least five newer drug options, most added on top of blood-pressure and SGLT2 medicines.